transduction cascades, which jointly optimized the expression of target gene profiles to promote fatty acid oxidation and accelerate glucose uptake and utilization than PPARg full agonist rosiglitazone without stimulating PPARa activity. Thus, GQD showed antidiabetic/or antihyperglycemic effects, partially through regulating adipocytic PPARa and PPARg signaling systems to maintaining balanced glucose and lipid metabolisms. This study provides a new insight into the anti-diabetic effect of GQD as a PPARa/g dual agonist to accelerate the clinical use.